|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2008
Decision Resources, Inc., April 2008, Pages: 43
Introduction
Spending on prescription drugs continues to grow in worldwide markets—but not as fast as other healthcare expenditures. Consequently, the pharmaceutical industry’s relatively modest share of total healthcare costs—less than 15% in most mature markets—is declining in many countries. Yet, despite this trend, governments and other payers continue to focus their cost-cutting strategies on the pharmaceutical market—politically, the least controversial target for economic controls. Government reforms are expected in a number of countries, which will further confound the pharmaceutical industry’s attempts to bring new therapies to market.
Get the Answers You Need to Shape Your Strategy
- Recent sales data point to a pronounced slowdown in the world’s leading pharmaceutical markets. How will this trend affect manufacturers’ growth strategies? Which sectors of the market were not affected by slower growth? What factors contributed to the slowdown in the U.S. market? How is the European market expected to manage this downturn?
- U.S. healthcare spending is expected to increase steadily over the next 10 years. What revisions in Medicare Part D will be made to control government costs, and what affect will these measures have on the pharmaceutical industry? How will health technology assessment (HTA) initiatives affect the reimbursement system in the United States?
- France and Germany are set to introduce major healthcare reforms in 2008. How much government intervention will take hold and will another round of changes be effective? Will mandated use of generics play a role in these reforms? What impact will potential “health evaluation systems” have in the emerging therapies arena?
- Pharmaceuticals now account for a declining share of healthcare spending in the United Kingdom. What government actions are expected to replace the current Pharmaceutical Price Regulation Scheme? What kind of reimbursement agreements will manufacturers need to negotiate?
Scope
- Issues affecting the pharmaceutical industry in the United States: continued criticism of drug prices; proposal for income-dependent premiums for Medicare Part D; delay in implementation of average manufacturer price (AMP)-based reimbursement in Medicaid.
- Issues affecting the pharmaceutical industry in Europe and Japan: plans in 2008 for healthcare reforms in France and Germany; innovation focused on oncology and orphan diseases; reference pricing in Spain slows growth in pharmaceutical expenditures; biennial drug price revisions and a focus on growing the generics market will continue in Japan.
- Issues affecting the pharmaceutical industry in the United Kingdom: the Pharmaceutical Price Regulation Scheme
Key Developments in the First Quarter of 2008
- Reductions in Medicare Hospital Outpatient Reimbursement
- European Commission Launches Major Antitrust Investigation
- Voluntary Rebate Contracts, Cost-Sharing Deals, and Risk-Sharing Agreements in Germany
- Signifi cant Reforms in Italy’s Finance Act 2008
- Court Ruling Strengthens Intellectual Property Protection in Spain
- Government Response to Parliamentary Review of NICE
- Limited Changes to the Japanese Pricing and Reimbursement System
Also available
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2008
Customers who bought this item also bought
Pharmaceutical Pricing and Reimbursement in the United Kingdom, 2008
Strategic Overview of Pharmaceutical Pricing and Reimbursement in the Major Markets
Pharmaceutical Pricing and Reimbursement in Japan, 2008
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2008
Pharmaceutical Pricing and Reimbursement in Italy, 2008
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Second Quarter of 2007
Special Report: Pharmaceutical Pricing and Reimbursement in Germany, 2008
Pharmaceutical Pricing and Reimbursement in the United States, 2008
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Third Quarter of 2007
Pharmaceutical Market Access, Pricing, and Reimbursement News in the Second Quarter of 2009
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2007
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the Fourth Quarter of 2006
|
|
|
|
